

Peer Review File

Article information: <https://dx.doi.org/10.21037/shc-22-60>

Reviewer Comments

Reviewer A:

Comment: The authors report a concise review of the changing landscape regarding extent of resection in lung cancer. The report is clear, and offers a strong review of the JCOG trial that has been met with such excitement. The authors do mention the CALGB trial, which, although not published, has been reported in several forums. I believe the manuscript would be strengthened by offering more results from this trial, especially as a means of comparing to the JCOG trial.

Reply: Thank you for your review. The results of the CALGB trial have indeed been recently presented and we integrated them in our commentary.

Reviewer B:

Comment: This article is an editorial commentary on lobectomy for stage IA NSCLC, with a focus on segmentectomy based on the recently published JCOG0802 trial. It is well-written.

Understand this article primarily focuses on surgical management -one minor comment I have is that author may consider briefly mention about SBRT. Approximately 25% early-stage lung cancer patients are not considered as surgical candidates at all and SBRT may be the only alternative option. (Chang JY et al. The Lancet Oncology 2015). In addition, there is a recently published article comparing the adverse events between SBRT vs sublobar resection PMID: 35816617.

Reply: Thank you for your review. Keeping the main focus of our commentary on the comparison between the two different surgical approaches, we have added a brief paragraph about the role of SBRT as an alternative to surgery. It is an interesting and intense matter and surely will need to be investigated in depth in the future.